656227-27-9Relevant articles and documents
Discovery of a Potent Botulinum Neurotoxin A Inhibitor ZM299 with Effective Protections in Botulism Mice
Gao, Jie,He, Zhili,Hong, Zhanying,Li, Tao,Luo, Deyan,Miao, Zhenyuan,Ning, Nianzhi,Wang, Hui,Wang, Jianxin,Wu, Yuelin,Xv, Xiguo,Zhang, Wannian,Zhang, Yanming,Zhuang, Chunlin
, p. 357 - 364 (2021/12/24)
Botulinum neurotoxins serotype A (BoNT/A) is the deadliest toxins known to humans and the "Category A" agent for bioterrorism. Over the past 20 years, significant efforts have been put forth to develop effective inhibitors of BoNT/A. Unfortunately, few id
4-aminoacylphenoxyacetamide compound and medicine uses thereof
-
Paragraph 0053; 0054; 0055; 0061; 0062; 0063; 0064, (2016/10/08)
The invention belongs to the field of pharmaceutical chemistry, and relates to 4-aminoacylphenoxyacetamide compound shown as an I formula and medicine uses thereof, and in the formula, G, Z, R, m and n are described in the specification in detail. The compounds are capable of inhibiting sphingomyelin synthase activity, and are applicable to treat diseases caused by abnormal increase of sphingomyelin level. The invention further comprises compounds shown as the formula I structure, pharmaceutically-acceptable salts thereof, and application of pharmaceutical composition taking the compounds or salts thereof as an effective active composition to prevent and treat diseases caused by abnormal increase of sphingomyelin level. The diseases caused by abnormal increase of sphingomyelin level comprise atherosclerosis, fatty liver, obesity, II type diabetes and other metabolic syndrome.
